Smruthi Organics gets rating up-gradation for bank facilities from CRISIL

25 Jul 2011 Evaluate

Credit rating agency, CRISIL has upgraded its ratings on the bank facilities of Smruthi Organics to ‘BBB/Stable/ A3+’ from ‘BBB-/Stable/CRISIL A3’.

The upgrade reflects CRISIL’s belief that Smruthi Organics will sustain the improvement in its financial risk profile over the medium term. The company reported a strong compound annual growth rate of 49% in its revenues over the past two years, while maintaining its moderate operating margin, supported by its strong clientele.

The ratings reflect the company’s established market position, supported by good client relations, and moderate financial risk profile marked by moderate gearing and debt protection metrics. These rating strengths are partially offset by the company’s limited product diversity, the intense market competition it faces, and its aggressively debt-funded capex plans.

Smruthi Organics commenced operations by manufacturing active pharmaceutical ingredients (APIs). The company manufactures bulk drugs, drug intermediates, and APIs. The key APIs manufactured by the company are norfloxacin, metformin, zidovudin, and amlodipine.

Smruthi Organics Share Price

117.65 -0.20 (-0.17%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.